Market Place
Sourcing Support
InflaRx Receives CHMP Opinion for GOHIBIC® in SARS-CoV-2 ARDS
15 Nov 2024 //
GLOBENEWSWIRE
InflaRx Reports Q3 2024 Financial Results & Business Update
08 Nov 2024 //
GLOBENEWSWIRE
InflaRx Presents Shine Trial Vilobelimab Analysis At EADV
25 Sep 2024 //
GLOBENEWSWIRE
InflaRx Presents INF904 Preclinical Data at European Complement Meeting
03 Sep 2024 //
GLOBENEWSWIRE
InflaRx Announces Participation in September Investor Events
27 Aug 2024 //
GLOBENEWSWIRE
InflaRx Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
InflaRx to Report Second Quarter 2024 Results on August 8, 2024
01 Aug 2024 //
GLOBENEWSWIRE
InflaRx To Present INF904 Preclinical Data At Complement Conference
30 Jul 2024 //
GLOBENEWSWIRE
InflaRx`s GOHIBIC Selected for BARDA-Sponsored ARDS Clinical Trial
24 Jun 2024 //
GLOBENEWSWIRE
InflaRx Hosts R&D Event Highlighting the Promise of INF904
05 Jun 2024 //
GLOBENEWSWIRE
InflaRx Shows Vilobelimab Potential Synergy In Severe COVID-19 At ATS
21 May 2024 //
GLOBENEWSWIRE
InflaRx Q1 2024 Financials, Business Update
08 May 2024 //
GLOBENEWSWIRE
InflaRx Virtual R&D Event on June 5, Q1 2024 Results on May 8
30 Apr 2024 //
GLOBENEWSWIRE
InflaRx Participates at Capital One Biotech Event
24 Apr 2024 //
GLOBENEWSWIRE
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
21 Mar 2024 //
GLOBENEWSWIRE
InflaRx to Announce Development Plans for INF904 & 2023 Financial Results
19 Mar 2024 //
GLOBENEWSWIRE
InflaRx Announces Initiation of its Commitment Program for GOHIBIC
25 Jan 2024 //
GLOBENEWSWIRE
InflaRx Announces Positive Topline Results from MAD Phase I Study with INF904
04 Jan 2024 //
GLOBENEWSWIRE
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab
06 Nov 2023 //
GLOBENEWSWIRE
InflaRx Reports Third Quarter 2023 Financial Results & Provides Business Update
01 Nov 2023 //
GLOBENEWSWIRE
InflaRx Announces Positive Results from Ph I Study with C5aR Inhibitor INF904
11 Sep 2023 //
GLOBENEWSWIRE
InflaRxs Marketing Authorization Application (MAA) for Vilobelimab
30 Aug 2023 //
GLOBENEWSWIRE
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
10 Aug 2023 //
GLOBENEWSWIRE
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
28 Jun 2023 //
GLOBENEWSWIRE
InflaRx Announces Commercial Launch of Gohibic vilobelimab
21 Jun 2023 //
GLOBENEWSWIRE
InflaRx Reports First Quarter 2023 Financial and Operating Results
11 May 2023 //
GLOBENEWSWIRE
InflaRx Announces Closing of the Full Exercise of Greenshoe Option
18 Apr 2023 //
GLOBENEWSWIRE
InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
14 Apr 2023 //
GLOBENEWSWIRE
InflaRx Announces Public Offering of Ordinary Shares
11 Apr 2023 //
GLOBENEWSWIRE
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
11 Apr 2023 //
GLOBENEWSWIRE
InflaRx plans to launch Covid antibody with five-figure price tag
05 Apr 2023 //
ENDPTS
InflaRx Receives FDA Emergency Use Authorization for Gohibic
04 Apr 2023 //
GLOBENEWSWIRE
FDA authorizes InflaRx`s anti-inflammation drug for severe COVID
04 Apr 2023 //
FIERCE PHARMA
InflaRx Reports Full Year 2022 Financial and Operating Results
22 Mar 2023 //
GLOBENEWSWIRE
InflaRx Announces Amendment of Co-Development Agreement Equity Investment
21 Dec 2022 //
GLOBENEWSWIRE
InflaRx Initiates First-in-Human Study with Small Molecule C5aR Inhibitor INF904
09 Nov 2022 //
GLOBENEWSWIRE
InflaRx seeks US FDA authorisation for Covid-19 treatment
30 Sep 2022 //
PHARMACEUTICAL-TECHNOLOGY
InflaRx Submits Request for Emergency Use Authorization to US FDA Vilobelimab
29 Sep 2022 //
GLOBENEWSWIRE
InflaRx to Present at Upcoming Scientific and Investor Conferences
09 Sep 2022 //
GLOBENEWSWIRE
InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19
08 Sep 2022 //
GLOBENEWSWIRE
InflaRx to take failed COVID treatment to FDA anyway
28 Jul 2022 //
FIERCEBIOTECH
InflaRx Announces Plans to Apply for EUA from FDA for Vilobelimab for COVID-19
26 Jul 2022 //
GLOBENEWSWIRE
InflaRx Receives FDA FTD for Treatment of Ulcerative Pyoderma Gangrenosum
06 Jul 2022 //
GLOBENEWSWIRE
InflaRx Provides Update for Vilobelimab in Pyoderma Gangrenosum and COVID-19
29 Jun 2022 //
GLOBENEWSWIRE
InflaRx to Present at the H.C. Wainwright Global Investment Conference
17 May 2022 //
GLOBENEWSWIRE
InflaRx Reports First Quarter 2022 Financial and Operating Results
12 May 2022 //
GLOBENEWSWIRE
InflaRx Shows Phase III Topline Results from PANAMO Trial of Vilobelimab
31 Mar 2022 //
GLOBENEWSWIRE
InflaRx Reports Full Year 2021 Financial and Operating Results
24 Mar 2022 //
GLOBENEWSWIRE
InflaRx Receives Advice Letter from FDA PIII Program for Vilobelimab
17 Mar 2022 //
GLOBENEWSWIRE
InflaRx says Vilobelimab Trial in Pyoderma Gangrenosum
08 Mar 2022 //
GLOBENEWSWIRE
Infla Rx Provides Update on Vilobelimab in Hidradenitis Suppurativa
28 Feb 2022 //
GLOBENEWSWIRE
InflaRx Reports Progress in Phase II Trial with Vilobelimab in cSCC
16 Feb 2022 //
GLOBENEWSWIRE
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
10 Jan 2022 //
GLOBENEWSWIRE
InflaRx Announces Positive Data from Phase II IXCHANGE Study with Vilobelimab
15 Nov 2021 //
GLOBENEWSWIRE
Cassava being investigated by unnamed `government agencies`; And more
15 Nov 2021 //
ENDPTS
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study
27 Oct 2021 //
GLOBENEWSWIRE
InflaRx Awarded up to EUR 43.7 Million Grant by German Government to Advance
19 Oct 2021 //
GLOBENEWSWIRE
InflaRx Completes Enrollment of Vilobelimab Phase III Study in Severe COVID-19
12 Oct 2021 //
GLOBENEWSWIRE
InflaRx to Develop Vilobelimab in Hidradenitis Suppurativa with new study data
08 Sep 2021 //
GLOBENEWSWIRE
InflaRx to Present at the BTIG Virtual Biotechnology Conference
06 Aug 2021 //
GLOBENEWSWIRE
